These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36412437)

  • 1. Stromal microenvironment namely angiogenesis, tumor-infiltrating lymphocytes, and matrix metalloproteinase in invasive breast carcinoma: Do they have a prognostic role?
    Srivastava G; Pant L; Kudesia M; Singh S; Gupta R
    J Cancer Res Ther; 2022; 18(6):1733-1737. PubMed ID: 36412437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis.
    Jana SH; Jha BM; Patel C; Jana D; Agarwal A
    Indian J Pathol Microbiol; 2014; 57(4):530-6. PubMed ID: 25308002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.
    Makretsov NA; Hayes M; Carter BA; Dabiri S; Gilks CB; Huntsman DG
    Mod Pathol; 2007 Jan; 20(1):84-9. PubMed ID: 17143263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal expression of CD10 in invasive breast carcinoma and its association with tumour stage, grade, ER, PR and HER2 status.
    Kamarudin NA; Abd Shukor N; Farouk WI; Muhammad Hanapi NA; Mohammed F
    Malays J Pathol; 2021 Dec; 43(3):389-396. PubMed ID: 34958060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma.
    Vo TN; Mekata E; Umeda T; Abe H; Kawai Y; Mori T; Kubota Y; Shiomi H; Naka S; Shimizu T; Murata S; Yamamoto H; Ishida M; Tani T
    Breast Cancer; 2015 Mar; 22(2):117-28. PubMed ID: 23575921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
    Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
    Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of CD10 positivity of stromal cells in core needle biopsy specimen of breast cancer patients and its relation with histological grade and lymphovascular invasion.
    Boler AK; Akhtar S; Bandyopadhyay A; Bandyopadhyay G
    Indian J Pathol Microbiol; 2021; 64(3):460-463. PubMed ID: 34341253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.
    Glajcar A; Łazarczyk A; Tyrak KE; Hodorowicz-Zaniewska D; Streb J; Okoń K; Szpor J
    Virchows Arch; 2021 Nov; 479(5):871-882. PubMed ID: 34117905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome.
    Iwaya K; Ogawa H; Izumi M; Kuroda M; Mukai K
    Virchows Arch; 2002 Jun; 440(6):589-93. PubMed ID: 12070597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer - a preliminary study.
    Thomas S; Babu RJ; Agarwal K; Puri V; Jain M; Andley M; Tudu SK
    Indian J Cancer; 2013; 50(1):46-51. PubMed ID: 23713046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
    Wang Y; Brodsky AS; Xiong J; Lopresti ML; Yang D; Resnick MB
    Clin Breast Cancer; 2018 Jun; 18(3):e373-e379. PubMed ID: 28890185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.
    Desmedt C; Majjaj S; Kheddoumi N; Singhal SK; Haibe-Kains B; El Ouriaghli F; Chaboteaux C; Michiels S; Lallemand F; Journe F; Duvillier H; Loi S; Quackenbush J; Dekoninck S; Blanpain C; Lagneaux L; Houhou N; Delorenzi M; Larsimont D; Piccart M; Sotiriou C
    Clin Cancer Res; 2012 Feb; 18(4):1004-14. PubMed ID: 22235100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Significance of CD10 Expression in Invasive Breast Carcinoma in Tunisian Patients.
    Makni S; Mellouli M; Saguem I; Boudawara O; Gouiaa N; Boudawara TS; Feki J; Kallel R
    Gulf J Oncolog; 2022 Sep; 1(40):15-23. PubMed ID: 36448066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype.
    Louhichi T; Saad H; Dhiab MB; Ziadi S; Trimeche M
    BMC Cancer; 2018 Jan; 18(1):49. PubMed ID: 29306324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal CD10 expression in gastric adenocarcinoma.
    Aziz SJ; Jalal JA; Hamadameen KS
    J Med Life; 2022 May; 15(5):679-684. PubMed ID: 35815076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.
    Tsutsui S; Yasuda K; Suzuki K; Tahara K; Higashi H; Era S
    Oncol Rep; 2005 Aug; 14(2):425-31. PubMed ID: 16012726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma.
    Kim HS; Kim GY; Kim YW; Park YK; Song JY; Lim SJ
    Histopathology; 2010 May; 56(6):708-19. PubMed ID: 20546336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.
    Hussien MT; Helmy E; Elsaba TM; Elkady A; Alrefai H; Hetta HF
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1573-1583. PubMed ID: 32592351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Infiltrating Lymphocytes/Plasmocytes in Chemotherapeutically Non-Influenced Triple-Negative Breast Cancers - Correlation with Morphological and Clinico-Pathological Parameters.
    Kolečková M; Kolář Z; Ehrmann J; Kořínková G; Zlámalová N; Melichar B; Trojanec R
    Klin Onkol; 2019; 32(5):380-387. PubMed ID: 31610672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.